



# The Effectiveness of Endoscopic Surgery of Juvenile Angiofibroma Using Surgical Glue

Seyed-Hadyi Samimi Ardesan<sup>1</sup>, Mojtaba Mohammadi Ardehali<sup>1</sup>, Najmeh Doustmohammadian<sup>2\*</sup>

<sup>1</sup>Department of Otorhinolaryngology, School of Medicine, Tehran University of Medical Sciences, Amiralam Hospital, Tehran, Iran; <sup>2</sup>Department of Otorhinolaryngology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran

## Abstract

**Edited by:** Ksenija Bogoeva-Kostovska  
**Citation:** Ardesan S-HS, Ardehali MM, Doustmohammadian N. The Effectiveness of Endoscopic Surgery of Juvenile Angiofibroma Using Surgical Glue. Open Access Maced J Med Sci. 2020 Mar 24; 8(B):150-154. <https://doi.org/10.3889/oamjms.2020.4253>  
**Keywords:** Juvenile nasopharyngeal angiofibroma; Embolization; Glubran; Blood loss  
**\*Correspondence:** Najmeh Doustmohammadian, Department of Otorhinolaryngology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran. Tel.: 02333437842. E-mail: [n\\_dostmohammadian@yahoo.com](mailto:n_dostmohammadian@yahoo.com)

**Received:** 31-Dec-2019

**Revised:** 14-Jan-2020

**Accepted:** 28-Feb-2020

**Copyright:** © 2020 Seyed-Hadyi Samimi Ardesan, Mojtaba Mohammadi Ardehali, Najmeh Doustmohammadian

**Funding:** This research did not receive any financial support

**Competing Interests:** The authors have declared that no competing interests exist

**Open Access:** This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)

**AIM:** The current study aimed to provide a method for juvenile nasopharyngeal angiofibroma embolization using Glubran glue in patients with low stage tumor. This method not only has less blood loss and good visualization but also impose a low cost, where no pre-operative embolization complications were found for this procedure.

**METHODS:** Between 2012 and 2014, 30 patients with angiofibroma undergoing endoscopic surgery. Age, sex, tumor stage, average blood loss, complications, length of hospitalization, and recurrence rate of the tumor were the main measured outcomes. Furthermore, 30 patients were divided into three groups with matched age, sex, and tumor staging. Group 1 received glue (Glubran), while Group 2 selected for study without glue and embolization and pre-operative embolization was considered for Group 3.

**RESULTS:** Based on the amount bleeding, the mean blood hemorrhage in Groups 1, 2, and 3 was 510, 1655, and 800 ml, respectively, the difference of hemorrhage between Groups 1 and 2 was found to be statistically significant ( $p = 0.007$ ). Blood loss in Group 1 was found to be less than Group 3, but the difference of hemorrhage between Group 1 and 3 was not statistically significant ( $p = 0.678$ ). No blood transfusion and complication were recorded for individuals in Group 1. The recurrence was found in 1 patient (10%) in both groups of 2 and 3, and no patient (0%) in Group 1.

**CONCLUSIONS:** The direct intraoperative embolization technique with glue was capable of providing a more complete and targeted embolization of the tumor. Some advantages can be mentioned for this technique, including decreased blood loss, less radiation exposure, lower rates of complications, and recurrence, as well as shorter hospitalization time, the ease of procedure with a spinal needle and low cost.

## Introduction

Juvenile nasopharyngeal angiofibroma (JNA) is defined to be benign and locally aggressive vascular tumor, affecting adolescent males [1]. JNA is responsible for 0.5% of head and neck tumors. Although this tumor is considered to be commonly occurred in nasopharynx, there are reports of its presence in the nasal septum, inferior and middle turbinate, hard palate, and alveolar ridge [2], [3], [4], [5], [6]. The prevalence of JNA is estimated to be 1/150,000–1/1,500,000 individuals [7], [8], [9], [10]. Previous studies indicated that disease was more prevalent in the Indian and Middle Eastern populations as compared to European populations [11]. Diagnosis of the tumor is usually based on the location of origin, post-contrast hypervascularization, and growth patterns [12], [13]. JNA typically receives vascular nutrition from the external carotid system, especially the internal maxillary, ascending pharyngeal, and vidian arteries [14], where vessels from the branches of the internal carotid artery, such as the Inferior hypophyseal artery, are commonly found in lesions involving the cranial base [15].

Many therapeutic modalities have been applied for treating this tumor. Non-surgical treatments include the use of hormones (estrogen and testosterone), radiotherapy, chemotherapy, and more recently embolization. Surgery and radiotherapy are among the most effective procedures [16], [17], [18]. Surgery is the therapeutic choice based on the stage of the tumor and the patient's general condition. For many years, several acceptable numerous approaches have been applied for decreasing morbidity and mortality of tumors. There are various opinions regarding the pre-operative embolization in the surgical treatment of this tumor; some surgeons believed that embolization was acceptable method, while others oppose it [19], [20], [21], [22], [23]. Pre-surgical tumor embolization for hypervascular neoplasms results in improved surgical outcomes reduced intraoperative bleeding and facilitating tumor resection [24]. Polyvinyl alcohol is the most commonly used embolization material that should be performed 24–48 h before surgery for avoiding revascularization [15].

Studies have shown that bilateral embolization of the internal maxillary artery was capable of improving treatment efficacy when the tumor received blood from bilateral external carotid artery [25]. In the past, to

control bleeding originating from the internal carotid artery in a lesion with extensive skull base involvement, a direct transcatheter lateral embolization technique with a combination of cyanoacrylate, lipiodol, and tungsten powder was proposed [26].

Some recent reports have introduced embolic agent Onyx with a non-migratory and bleeding-reducing property that has significant therapeutic performance, where the interest in this new treatment has increased [27], [28]. Due to the complications of pre-operative embolization, this study aimed to reduce the amount of bleeding during surgery and improve visual acuity, and to minimize the complications of pre-operative embolization and costs.

## Materials and Methods

Between 2012 and 2014, 30 patients with angiofibroma undergoing endoscopic surgery in ear, nose, and throat department of Amir A'lam Hospital were enrolled in the study.

Exclusion criteria included pregnancy, history of malignancy, history of previous surgery, patients with Stage IIc above, and patients with other systemic diseases such as Wagner's disease. All patients were included in the study with written consent. However, due to ethical considerations, patient information was kept confidential. All patients were radiologically and surgically classified with Radkowski staging system.

Thirty patients were divided into three groups. The patient group (Group 1) consisted of 10 patients who underwent endoscopic surgery with surgical Glubran glue. The control group (Group 2) consisted of 10 patients without surgical glue and embolization. The third group (Group 3) consisted of 10 patients who underwent embolization surgery. Groups were matched for such factors as sex, age range, and stage of the tumor by propensity score matching method.

### Methods

After the patients under hypotensive anesthesia, 0.5 cc glue was injected with normal saline for the patients group. It is worth noting that 0.5 cc surgical glue Glubran in combination with n-butyl 2-cyanoacrylate adhesive was used. Subsequently, tumor bulk was pushed into the nasopharyngeal space by a medium-sized FREER Septum Elevator and adrenaline soaked on gauze. Then, the surgical process continued, depending on the tumor spread. For example, in the case of tumor expansion to the pterygomaxillary fissure, surgery was performed by removing the posterior wall of the maxillary sinus and pushing it toward the medial side. If the tumor had a lateral extension to infratemporal fossa, force was

applied from the lateral to the medial with the freer and gauze. Surgical meshes were used for cavernous sinus bleeding while the anesthesia team was ready to treat severe bleeding. The mass was completely removed by the use of DAVIS Mouth Gags and large-size forceps after pushing the bulk of the tumor into the nasopharynx and the oropharynx. Suction electrocautery and bipolar were used for homeostasis. These tumors were never resected in a piecemeal manner. At the end of the operation, an examination of the remaining tissues and sites of abnormal bleeding was performed. In addition, all surgeries are performed by one surgeon.

Prophylactic drilling of the clivus or pterygoid root and sphenoid diploe and vidian canal was also performed on patients who had obvious bone involvement in these locations.

### *Evaluation of bleeding rate, injection blood, and duration of hospitalization*

All patients were compared regarding the amount of intraoperative bleeding, the amount of tumor bleeding based on the surgeon's opinion, the amount of blood transfused the length of stay after surgery, complications, amount of residual tumor, and recurrence. The volume of intraoperative bleeding was calculated based on the counting number of blooded gauze and the volume of suctioned blood. All patients undergoing endoscopic angiofibroma surgery were evaluated endoscopically 2 weeks after surgery, and then evaluated for the first 6 months monthly and then annually. A computed tomography (CT) evaluation was performed in the 3<sup>rd</sup> month after surgery. If endoscopic abnormalities were seen during the examination of recurrent patients, the findings were confirmed by contrast-enhanced CT (CECT). Diagnosis of recurrent angiofibroma was also assessed based on clinical symptoms and CECT scans and sometimes magnetic resonance imaging. The mean follow-up period was  $8.8 \pm 3.16$  for Group 1 followed by  $24.3 \pm 17.56$  months for Group 2 and  $10 \pm 7.53$  months for Group 3.

### *Statistical analysis*

After data collection, the Data Bank was prepared by SPSS software version 19 and the data were entered. T-test was used to compare the results. In all cases,  $p < 0.05$  was considered statistically significant.

## Results

In this study, 30 patients underwent surgery, all of whom were male. The mean age of Group 1 was  $18.5 \pm 5.56$  followed by  $18.2 \pm 5.56$  for Group 2 and  $17.5 \pm 4.10$  for Group 3. Patients in each group had

Stage IIc (9 patients) and IIb (1 patient). The three groups were matched for age, sex, and stage of the disease (Table 1).

**Table 1: Characteristics of the three groups of patients with angiofibroma according to sex, sex, and stage of disease**


Character	Group 1		Group 2		Group 3		p-value
Age	18.5±5.56		18.2±5.06		17.5±4.10		0.907
Sex	Female	Male	Female	Male	Female	Male	1
	0	10	0	10	0	10	
Disease stage	IIc	IIb	IIc	IIb	IIc	IIb	1
	9	1	9	1	9	1	

As can be seen in Table 2, the most common symptom was a nasal obstruction in 29 patients (96.7%) followed by epistaxis in 18 patients (60%). One patient also had a headache (3.3%).

**Table 2: The most common clinical symptoms of angiofibroma patients at the time of referral based on the three groups**

Studied groups	Frequency of clinical symptoms at the time of referral		
	Frequency of nasal obstruction (%)	Epistaxis frequency (%)	Headache Frequency (%)
The first group (surgical technique using glue)	10 (100)	6 (60)	0
The second group (surgery without the use of glue and embolization)	9 (90)	7 (70)	1 (10)
The third group (surgery with pre-operative embolization)	10 (100)	5 (50)	0
All patients	29 (96)	18 (60)	1 (3.3)

The number of people with mild, moderate, and severe bleeding is shown in Figure 1. In terms of bleeding rates, the average bleeding in Groups 1, 2, and 3 was determined as 510 cc, 1655 cc, and about 800 cc, respectively. There was a significant difference in the amount of bleeding between Groups 1 and 2 ( $p = 0.007$ ) and Groups 2 and 3 ( $p = 0.048$ ). Bleeding in Group 1 was lower than in Group 3, but there was no significant difference between Groups 1 and 3 ( $p = 0.678$ ). In Group 1, no blood unit was injected. The difference between Group 1 and 2 was significant ( $p = 0.004$ ).



**Figure 1: Number of people with mild, moderate, and severe bleeding depending on the surgeon's view for severity of bleeding**

Analysis of hospital stay variables showed no significant difference between groups (Table 3). Mean days of hospitalization in Group 1 were  $2.1 \pm 0.32$

**Table 3: Number of admission days after surgery in three groups of angiofibroma patients**

Patients	The number of hospitalization days	
	1-2 day	>2 day
Group 1	9	1
Group 2	6	4
Group 3	8	3
Significant	p=0.09	

followed by  $2.4 \pm 0.84$  in Group 2 and  $2.3 \pm 0.48$  days in Group 3. The mean days of admission were lower in Group 1.

The mean follow-up period for Group 1 was  $8.8 \pm 3.16$  months followed by  $24.3 \pm 17.56$  months for Group 2 and  $10 \pm 7.53$  months for Group 3. The recurrence rate in Group 1 was 0% and Groups 2 and 3 each had one recurrent patient (10%). An 18-year-old patient was recorded for Group 2 and a 13-year-old patient for Group 3, both of whom were in Stage IIc. There was no significant difference in the recurrence rate between Groups 1 and 2 and 3 ( $p = 0.754$ ).

## Discussion

The direct percutaneous approach using liquid embolic materials such as glue or onyx is the most widely used approach. The benefits of onyx over glue are primarily due to the slower rate of polymerization which allows deeper penetration within the tumor vasculature, in contrast to the instant polymerization of glue on contact with blood that prevents uniform and controlled penetration of the tumor vasculature [27], [29].

Another liquid embolic agent commonly used in practice is Fibrin. Fibrin glue has been used in neurosurgery, pharmacology, vascular surgery, pre-operative embolization of the patient with intracranial meningioma, closure of the dura, and prevention of spinal fluid leaks [30]. In addition, fibrin glue spray has been effective in fixing mucoperichondrium to cartilage instead of suture [31]. The present study investigated the effect of glue on post-operative health factors of patients. According to our findings, the amount of bleeding was lowest in the group with glue, where the complications of blood transfusion were minimal.

Intraoperative use glue appears to block intratumor vessels and reduces intraoperative hemorrhage while it may be a useful measure to reduce bleeding in tumors with bilateral blood supply and internal carotid blood supply. The use of embolic agents has played an important role in the treatment of patients [27], [28]. Elhammady *et al.* have compared pre-operative transarterial embolization and embolization with onyx via direct tumoral puncture [32].

However, it should be noted that complications after the use of embolic agents are

important, and all studies on embolization have not been fully successful [26]. Ethylene-vinyl alcohol copolymer embolic agent has been studied for the direct percutaneous embolization of angiofibroma with complications such as trigeminal cardiac reflex [33], [34], [35]; however, the advantage of onyx is the absence of side effects and a positive effect on bleeding [29]. The success criteria for any tumor surgery is depend on the recurrence rate. The recurrence rate of angiofibroma has been reported in some studies (7–39.5%) [36] and some studies have reported a recurrence rate of 25–46%, where a rate of 25% was reported for Stage IIc and 40–50% for Stage III [37], [38], [39], [40]. In our study, no recurrence was seen in Group 1 that is different from other studies; this difference may be related to the selection of patients with Stage IIc (below). In a recent study, three factors were predictive of a recurrence rate that including patient under 18 years of age at diagnosis, tumor size >4 cm, and advanced stage of disease, according to Radkowski's classification [41].

Our findings should take into consideration in light of limitations regarding a relatively short follow-up period of patients after surgery. Although most symptomatic relapses are expected to occur during the first 12 months after treatment [42], this can certainly be debated. Fibrin glue had a positive effect on reducing bleeding and requiring blood transfusion, which has been the main finding of our study.

There are a number of limitations to our study. In the first place, the number of cases included in this study is somewhat small which makes the generalization of results not possible. There is also some minor inaccuracy in estimated intraoperative blood loss due to the fact that adjustment is made for the surgical effluent containing both fresh blood and operative irrigation fluid.

Finally, it may be suggested that comprehensive studies are required with longer follow-up, and it is hoped that this method will be used as a routine technique in future angiofibroma operations.

## Conclusions

The direct embolization technique using surgical glue allows for more complete and targeted tumor embolization. The main advantage of this technique is the ease of procedure with a spinal needle which was associated with reduced exposure to radiation, less intraoperative bleeding, and lower cost. In addition, surgical glue injection can be used in all vascular tumors of the sinus cavities as a research and its application in tumor recurrence and advanced stages of angiofibroma tumor can also be evaluated.

## References

- Bakshi SS, Bhattacharjee S. Juvenile nasopharyngeal angiofibroma. *J Pediatr Hematol Oncol*. 2016;38(6):491-2. PMID:27164528
- Erdur ZB, Yener HM, Yilmaz M, Karaaltin AB, Inan HC, Alaskarov E, et al. Cellular Angiofibroma of the Nasopharynx. *J Craniofac Surg*. 2017;28(8):e720-e722. <https://doi.org/10.1097/scs.0000000000003845> PMID:28885437
- Capodiferro S, Favia G, Lacaita MG, Lo Muzio L, Maiorano E, et al. Juvenile angiofibroma: Report of a case with primary intra-oral presentation. *Oral Oncol Extra*. 2005;41:1-6. <https://doi.org/10.1016/j.ooe.2004.09.001>
- Handa KK, Kumar A, Singh MK, Chhabra AH. Extranasopharyngeal angiofibroma arising from the nasal septum. *Int J Pediatr Otorhinolaryngol*. 2001;58(2):163-6. [https://doi.org/10.1016/s0165-5876\(00\)00460-2](https://doi.org/10.1016/s0165-5876(00)00460-2) PMID:11278025
- Salimov A, Ozer S. A rare location of angiofibroma in the inferior turbinate in young woman. *Int Arch Otorhinolaryngol*. 2015;19(2):187-90. <https://doi.org/10.1055/s-0034-1398471> PMID:25992179
- Tan L, Loh T. Benign and malignant tumors of the nasopharynx. In: Flint PW, Haughey BH, Lund VJ, Niparko JK, Robbins KT, Thomas JR, Lesperance MM, editors. *Cummings Otolaryngology Head and Neck Surgery*. 6<sup>th</sup> ed. Philadelphia, PA: Elsevier, Saunders; 2015. p. 1420-31. <https://doi.org/10.1016/b978-0-323-05283-2.00100-2>
- Szymańska A, Szymański M, Czekańska-Chehab E, Szczerbo-Trojanowska M. Invasive growth patterns of juvenile nasopharyngeal angiofibroma: Radiological imaging and clinical implications. *Acta Radiol*. 2014;55(6):725-31. <https://doi.org/10.1177/0284185113506189> PMID:24132768
- McKnight CD, Parmar HA, Watcharotone K, Mukherji SK. Reassessing the anatomic origin of the juvenile nasopharyngeal angiofibroma. *J Comput Assist Tomogr*. 2017;41(4):559-64. <https://doi.org/10.1097/rct.0000000000000566> PMID:28632604
- Alshaiikh NA, Eleftheriadou A. Juvenile nasopharyngeal angiofibroma staging: An overview. *Ear Nose Throat J*. 2015;94(6):E12-22. <https://doi.org/10.1177/014556131509400615> PMID:26053985
- Tan G, Ma Z, Long W, Liu L, Zhang B, Chen W, et al. Efficacy of preoperative transcatheter arterial embolization for nasopharyngeal angiofibroma: A comparative study. *Cardiovasc Intervent Radiol*. 2017;40(6):836-44. <https://doi.org/10.1007/s00270-017-1587-3> PMID:28175976
- López F, Triantafyllou A, Snyderman CH, Hunt JL, Suárez C, Lund VJ, et al. Nasal juvenile angiofibroma: Current perspectives with emphasis on management. *Head Neck*. 2017;39(5):1033-45. <https://doi.org/10.1002/hed.24696> PMID:28199045
- Maroldi R, Nicolai P. *Imaging in Treatment Planning for Sinonasal Diseases*. New York, USA: Springer; 2004.
- Lloyd G, Howard L, Lund VJ, Savy L. Imaging for juvenile angiofibroma. *J Laryngol Otol*. 2000;114(9):727-30. <https://doi.org/10.1258/0022215001906642> PMID:11091844
- Lund VJ, Stammberger H, Nicolai P, Castelnuovo P, Beal T, Beham A, et al. European position paper on endoscopic



- management of tumours of the nose, paranasal sinuses and skull base. *Rhinol Suppl.* 2010;22:1-43.  
PMid:20502772
15. Wu AW, Mowry SE, Vinuela F, Abemayor E, Wang MB. Bilateral vascular supply in juvenile nasopharyngeal angiofibromas. *Laryngoscope.* 2011;121(3):639-43. <https://doi.org/10.1002/lary.21337>  
PMid:21344446
  16. Enepekides DJ. Recent advances in the treatment of juvenile angiofibroma. *Arch Otolaryngol Head Neck Surg.* 2004;12:495-9.
  17. Mcafee WJ, Morris CG, Andur RJ, Werning JW, Mendenhall WM. Definitive radiotherapy for juvenile nasopharyngeal angiofibroma. *Am J Clin Oncol.* 2006;29:168-70.
  18. Ye D, Shen Z, Wang G, Deng H, Qiu S, Zhang Y. Analysis of factors in successful nasal endoscopic resection of nasopharyngeal angiofibroma. *Acta Otolaryngol.* 2016;136(2):205-13. <https://doi.org/10.3109/00016489.2015.1099734>  
PMid:26492972
  19. Ferreira LM, Gomes EF, Azevedo JF, Souza J.R., Araújo RP, Rios AS. Endoscopic surgery of nasopharyngeal angiofibroma. *Rev Bras Otorrinolaringol.* 2006;72:475-80.
  20. Andrade NA, Pinto JA, Nóbrega MO, Aguiar JE, Aguiar TF, Vinhaes ES. Exclusively endoscopic surgery for juvenile nasopharyngeal angiofibroma. *Otolaryngol Head Neck Surg.* 2007;137(3):492-6. <https://doi.org/10.1016/j.otohns.2007.03.003>  
PMid:17765782
  21. Sirakov S, Sirakov A. Preoperative endovascular embolization of juvenile nasopharyngeal angiofibroma. *Int J Sci Res.* 2017;6:1434-6.
  22. Borghei P, Baradaranfar MH, Borghei SH, Sokhandon F. Transnasal endoscopic resection of juvenile nasopharyngeal angiofibroma without preoperative embolization. *Ear Nose Throat J.* 2006;85(11):740-3, 746. <https://doi.org/10.1177/014556130608501114>  
PMid:17168151.
  23. Garça MF, Yuca SA, Yuca K. Juvenile nasopharyngeal angiofibroma. *Eur J Gen Med.* 2010;7:419-425. <https://doi.org/10.29333/ejgm/82897>
  24. Zähringer M, Guntinas-Lichius O, Gossmann A, Wustrow J, Krüger K, Lackner K. Percutaneous embolization for cervicofacial neoplasms and hemorrhages. *ORL J Otorhinolaryngol Relat Spec.* 2005;67(6):348-60. <https://doi.org/10.1159/000090047>  
PMid:16327276
  25. Hackman T, Snyderman CH, Carrau R, Vescan A, Kassam A. Juvenile nasopharyngeal angiofibroma: The expanded endonasal approach. *Am J Rhinol Allergy.* 2009;23(1):95-9. <https://doi.org/10.2500/ajra.2009.23.3271>  
PMid:19379621
  26. Tranbahuy P, Borsik M, Herman P, Wassef M, Casasco A. Direct intratumoral embolization of juvenile angiofibroma. *Am J Otolaryngol.* 1994;15(6):429-35. [https://doi.org/10.1016/0196-0709\(94\)90084-1](https://doi.org/10.1016/0196-0709(94)90084-1)  
PMid:7872479
  27. Lehmann M, Ulrich S, Reineke U, Hamberger U, Dietrich U, Sudhoff H. Intratumoral Onyx embolisation in the management of juvenile nasopharyngeal angiofibroma. *HNO.* 2010;58(8):853-7. <https://doi.org/10.1007/s00106-010-2146-2>  
PMid:20596683
  28. Herman B, Bublik M, Ruiz J, Younis R. Endoscopic embolization with onyx prior to resection of JNA: A new approach. *Int J Pediatr Otorhinolaryngol.* 2011;75(1):53-6. <https://doi.org/10.1016/j.ijporl.2010.10.006>  
PMid:21051094
  29. Raissi D, Yu Q, Mardini SH. Upper gastrointestinal bleed embolization with onyx®: The "tattoo effect". *J Clin Imaging Sci.* 2018;8:46. [https://doi.org/10.4103/jcis.jcis\\_64\\_18](https://doi.org/10.4103/jcis.jcis_64_18)  
PMid:30546930
  30. Jankowitz BT, Atteberry DS, Gerszten PC, Karausky P, Cheng BC, Faught R, *et al.* Effect of fibrin glue on the prevention of persistent cerebral spinal fluid leakage after incidental durotomy during lumbar spinal surgery. *Eur Spine J.* 2009;18(8):1169-74. <https://doi.org/10.1007/s00586-009-0928-6>  
PMid:19283413
  31. Vaiman M, Sarfaty S, Eviatar E. The use of fibrin sealant as a glue for septoplasty and conchotomy. *Rhinology.* 2009;47(3):297-300. <https://doi.org/10.4193/rhin08.156>  
PMid:19839254
  32. Elhammady MS, Johnson JN, Peterson EC, Aziz-Sultan MA. Preoperative embolization of juvenile nasopharyngeal angiofibromas: Transarterial versus direct tumoral puncture. *World Neurosurg.* 2011;76(3-4):328-34. <https://doi.org/10.1016/j.wneu.2010.11.011>  
PMid:21986432
  33. Gemmete JJ, Patel S, Pandey AS, Sullivan SE, McKean EL, Marentette LJ, *et al.* Preliminary experience with the percutaneous embolization of juvenile angiofibromas using only ethylene-vinyl alcohol copolymer (Onyx) for preoperative devascularization prior to surgical resection. *AJNR Am J Neuroradiol.* 2012;33(9):1669-75. <https://doi.org/10.3174/ajnr.a3043>  
PMid:22499846
  34. Probst EN, Grzyska U, Westphal M, Zeumer H. Preoperative embolization of intracranial meningiomas with a fibrin glue preparation. *AJNR Am J Neuroradiol.* 1999;20(9):1695-702.  
PMid:10543643
  35. Shaffrey CI, Spotnitz WD, Shaffrey ME, Jane JA. Neurosurgical applications of fibrin glue: Augmentation of dural closure in 134 patients. *Neurosurgery.* 1990;26(2):207-10. <https://doi.org/10.1227/00006123-199002000-00004>  
PMid:2308667
  36. Danesi G, Panizza B, Mazzoni A, Calabrese V. Anterior approaches in juvenile nasopharyngeal angiofibromas with intracranial extension. *Otolaryngol Head Neck Surg.* 2000;122(2):277-83. [https://doi.org/10.1016/s0194-5998\(00\)70256-7](https://doi.org/10.1016/s0194-5998(00)70256-7)  
PMid:10652407
  37. Herman P, Lot G, Chapot R, Salvan D, Huy PT. Long-term follow-up of juvenile nasopharyngeal angiofibromas: Analysis of recurrences. *Laryngoscope.* 1999;109(1):140-7. <https://doi.org/10.1097/00005537-199901000-00027>  
PMid:9917056
  38. Gullane PJ, Davidson J, O'Dwyer T, Forte V. Juvenile angiofibroma: A review of the literature and a case series report. *Laryngoscope.* 1992;102(8):928-33. <https://doi.org/10.1288/00005537-199208000-00014>  
PMid:1323003
  39. Jorissen M, Eloy P, Rombaux P, Bachert C, Daele J. Endoscopic sinus surgery for juvenile nasopharyngeal angiofibroma. *Acta Otorhinolaryngol Belg.* 2000;54(2):201-19.  
PMid:10892510
  40. Howard DJ, Lloyd G, Lund V. Recurrence and its avoidance in juvenile angiofibroma. *Laryngoscope.* 2001;111(9):1509-11. <https://doi.org/10.1097/00005537-200109000-00003>  
PMid:11568597
  41. Sun XC, Wang DH, Yu HP, Wang F, Wang W, Jiang JJ. Analysis of risk factors associated with recurrence of nasopharyngeal angiofibroma. *J Otolaryngol Head Neck Surg.* 2010;39(1):56-61.  
PMid:20122346
  42. Quinn FB, Ryan MW, Ulualp S. Juvenile Nasopharyngeal Angiofibroma: Grand Rounds Presentation. USA: UTMB Department of Otolaryngology Head and Neck Surgery; 2007.